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ABSTRACT
Cell cycle checkpoints determine whether cells meet requirements to progress
through the next stage. In response to DNA damage, how cells activate checkpoints
have been well studied, but little is known about checkpoint deactivation (recovery),
which directly impacts on cell fate. In tumor cells, the signaling network has been
rewired due to epigenetic and genetic alterations, which result in resistance to the cell
cycle control, and thus resistance to chemotherapy or radiation therapy. Therefore, it is
critical to identify molecules required for checkpoint recovery or adaptation after DNA
damage.
To achieve this goal, we performed a multidisciplinary study combining reverse
phase protein array (RPPA) data, molecular biology and mathematical modeling to
systematically identify molecules required for DNA damage checkpoint recovery. The
mTOR complex 1 (mTORC1) plays an essential role to regulate mitotic entry after
irradiation. Inhibition of the mTOR pathway delayed G2/M checkpoint recovery, while
TSC2-null cells with hyperactivity of mTORC1 exhibited the opposite results.
Furthermore, our mechanistic study revealed that mTOR signaling pathway controls a
transcriptional program of mitotic entry through regulating histone lysine demethylase
KDM4B, which is required for the epigenetic regulation of key mitosis-related genes
including CCNB1 and PLK1.
Given accelerated G2/M checkpoint recovery in TSC2-null cells with mTORC1
hyperactivity, we postulated that further abrogation of the G2/M checkpoint may
facilitate mitotic catastrophe and selectively kill cells. As we expected, TSC2-null cells
IV

were more sensitive to the WEE1 inhibitor, a negative regulator of mitotic entry,
compared to wild-type cells.
In summary, we reported a novel mechanism of the mTORC1 signaling in
regulating a transcriptional program required for G2/M checkpoint recovery after DNA
damage. This mechanism provided a therapeutic strategy for TSC patients with
mTORC1 hyperactivity using the WEE1 inhibitor, which has a potential to be translated
into clinical trials.
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CHAPTER 1
Introduction

The mechanistic (or mammalian) target of rapamycin (mTOR) has been studied
for decades as a serine/threonine kinase with multiple functions. As part of the
mTORC1 and mTORC2 complexes, mTOR serves as a central regulator of cell
metabolism, cell growth, proliferation and survival in response to nutrients, growth
factors, energy levels and cellular stress (1). Recent studies provide insights into the
role of mTOR in signaling pathways involved in human diseases, stimulating interest in
mTOR as the target for disease treatment (2). In this study, a multidisciplinary
approach identified that the mTOR signaling network is associated with checkpoint
recovery after DNA damage which affects genomic instability, the major cause of many
diseases, including cancer. The link between nutritional status and genome integrity
may provide a comprehensive approach to biomedical science and clinical applications.

1.1 The PIKK family
mTOR belongs to the phosphatidylinositide 3-kinase (PI3K)-related kinase (PIKK)
family, which also comprises DNA protein kinase catalytic subunit (DNA-PKcs), ataxia
telangiectasia mutated (ATM),

ATM and Rad3-related (ATR), suppressor of

morphogenesis in genitalia (SMG1), and transformation/transcription associated protein
(TRRAP) (3-5). The functions of PIKK family include DNA damage response (DDR),
1

nutrient-dependent signaling, nonsense-mediated mRNA decay and transcription. They
share sequence similarity in the FRAP-ATM-TRRAP (FAT) domain, the PIKK domain
and the FAT C-terminal (FATC) domain in their C terminus. The region for proteinprotein interactions in the N terminus is poorly conserved, which controls the protein
activity and causes functional diversity (Fig. 1). The activity of DNK-PKcs in DNA
double strands breaks (DSBs) is regulated by KU70/80. ATM is also involved in the
cellular response to DSBs with the help of the MRE11-RAD50-NBS1 (MRN) complex.
ATR is activated by ATR-interacting protein (ATRIP), topoisomerase II β binding
protein 1 (TOPBP1), and Claspin at ssDNA sites, such as resected DSBs and stalled
replication forks, and ATR is associated with ssDNA damage repair and replication
origin firing. The functions of mTOR mainly rely on interactions with many proteins to
form different complexes (4, 6). Although PIKK family members interact with their own
partners, the members still have the possibility to collaborate with each other in
response to common environmental cues.

2

Figure 1 The domain structure of PIKKs
The diagram only shows the locations of the FRAP-ATM-TRRAP (FAT) domain, the
PI3K-related kinase (PIKK) domain, and the FAT C-terminal domain (FATC) in PIKK
family members, which share sequence similarity within these three domains.
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1.2 mTOR and the molecular composition of mTOR complexes
mTOR forms at least two protein complexes called mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). mTORC1 and mTORC2 share three components
including mTOR, mammalian lethal with Sec13 protein 8 (mLST8) and DEP-domaincontaining mTOR-interacting protein (DEPTOR). The kinase activity of mTOR is
enhanced by mLST8 which directly stabilizes the active site of mTOR (7) and is
negatively regulated by DEPTOR (8). The complex mTORC1 also contains regulatoryassociated protein of mTOR (Raptor) and another inhibitory regulator proline-rich AKT
substrate 40 kDa (PRAS40) (9-10). mTORC2 comprises rapamycin-insensitive
companion of mTOR (Rictor), mammalian stress-activated protein kinase interacting
protein (mSIN1) and protein observed with Rictor1 (PROTOR1) (1). Different
compositions of both complexes affect their activation and function. In general,
mTORC1 regulates cell growth in response of growth factor, nutrients, and stress tough
downstream effectors ribosomal protein S6 kinase (S6K) and eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1). mTORC2 controls cytoskeleton
rearrangement, cell proliferation and survival by phosphorylating and activating AKT
(known as protein kinase B, PKB), protein kinase C (PKC) and serum/glucocorticoid
regulated kinase 1 (SGK1) (11-12). Although mTORC1 and mTORC2 have their
downstream targets, crosstalk exists between two complexes. mTORC1 inhibits
mTORC2 tough S6K-mediated phosphorylation of Rictor at Thr1135 and inhibition of
S6K causes an increase of ATK phosphorylation at Ser473 by mTORC2

(13);

mTORC2 activates mTORC1 through ATK activation (14). It is difficult to completely
separate the connections between two complexes but in this study the focus is still on
mTORC1.
4

1.2.1 The signaling pathways of mTORC1
The activation of mTORC1 is in response to different upstream cues through
different pathways (Fig. 2). Insulin/growth factors activate mTORC1 via the PI3K/AKT
pathway and the mitogen-activated protein kinases (MAPK) pathway. Both pathways
control the upstream negative regulator of mTORC1, a trimeric complex (in this thesis,
the term “the TSC complex” will be used) composing of tuberous sclerosis complex 1
(TSC1, hamartin), TSC2 (tuberin), and TBC1 domain family member 7 (TBC1D7) (15).
AKT and MAPK phosphorylate TSC2 and inhibit the function of TSC2 as a GTPaseactivating protein (GAP), thus inhibiting GTP hydrolysis and promoting GTP-bound
RAS homolog enriched in brain (RHEB) GTPase to activate mTORC1 (16). AKT also
phosphorylates PRAS40, resulting in PRAS40 dissociation from mTORC1 and
mTORC1 activation (17).
Amino acids (AAs), particularly leucine and arginine, are crucial for mTORC1
activation. Even with sufficient growth factors, amino acids withdrawal still inhibits
mTORC1 signaling. AAs activate mTORC1 through another GTPase called the RASrelated GTP-binding protein (Rag) family of GTPase, a heterodimer of RAGA/RAGB
with RAGC/RAGD. With accumulation of amino acids in the lysosomal lumen, the
Ragulator complex anchors the Rag GTPase to the lysosome and activates the Rag
GTPase (RAGA/RAGBGTP-RAGC/RAGDGDP). The activated GTPase then recruits
mTORC1 to the lysosome through direct interaction with Raptor (18-19). Meanwhile,
AKT-mediated dissociation of the TSC complex from the lysosomal surface places
activated RHEBGTP and mTORC1 in the close proximity at the lysosome for mTORC1
activation (20-21).
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Figure 2 The signaling pathways related to mTORC1
The diagram briefly shows how mTORC1 responses to upstream cues through different
pathways. TF: transcription factor

6

Different types of stress can negatively regulate mTORC1 activity. Cellular
respiration, including glycolysis, Krebs circle and electron transport, is the process to
generate ATP from glucose. When cellular ATP levels drop due to nutrient deprivation,
AMP-activated kinase (AMPK) senses the increased ratios of AMP/ATP and inhibits
mTORC1 through phosphorylating TSC2 and Raptor. DNA damage also regulates
mTORC1 activity through P53-dependent upregulation of AMPK. P53 downstream
transcriptional targets Sestrin 1 and 2 activate AMPK, thus suppressing mTORC1
activity (17).
Activated mTORC1 phosphorylates downstream targets and regulates many
cellular processes, including transcription, translation, mRNA splicing, and autophagy.
The phosphorylated targets are involved in cell growth, cell proliferation, cell cycle,
metabolism, and stress response (22). For example, mTORC1 is the direct mediator
between nutritional condition and autophagy. In the presence of nutrients and growth
factors, PI3K/ATK, MAPK and AMPK are all upstream inhibitors of autophagy via
mTORC1 activation. Activated mTORC1 shuts down autophagy by phosphorylating
and inactivating unc-51 like autophagy activating kinase 1 (ULK1) and autophagy
related 13 (ATG13), which are required for the phagophore formation (23). Two wellknown mTORC1 targets, 4EBP1 and S6K, are translational regulators. 4EBP1
competes with eukaryotic translation initiation factor 4G (eIF4G) to form the complex
with eIF4E and inhibits eIF4E-dependent translation. Phosphorylation of 4EBP1 by
mTORC1 at Thr37/Thr46 decreases its binding affinity to eIF4E and activates eIF4Edependent translation (24). Phosphorylation of S6K by mTORC1 at Thr389 promotes
mRNA maturation and the synthesis of ribosomal mRNAs and proteins. They both
promote many proteins related to cell growth, such as c-MYC and Cyclin D (25).
7

mTORC1 also indirectly controls transcription factors related to metabolism and stress
response, which makes the role of mTORC1 even broader (26).
1.2.2 The summary of mTOR inhibitors
Rapamycin is the first generation of mTOR inhibitors. It inhibits the ability of
mTORC1, but not mTORC2, to phosphorylate substrates. Rapamycin binds FK506Binding Protein 1A (FKBP1A) and dissociates Raptor from mTOR, thus preventing the
access of mTOR to some substrates (27). Prolonged treatment with rapamycin may
also inhibit mTORC2 in some tissues and cell lines. This effect may involve progressive
sequestration of the mTOR pool in a complex with rapamycin-FKBP12, thus making it
unavailable for mTORC2 (17). Rapamycin analogs (rapalogs), such as temsirolimus
(intravenous) and everolimus (oral), have been approved for advanced renal cell
carcinoma treatment, but not for the majority of cancer therapy (28). For example, a
prospective, randomized phase III study shows that everolimus is associated with a
survival benefit of 6.3 months in patients with advanced pancreatic neuroendocrine
tumors, but the finding is not statistically significant (29). One reason why it is more
cytostatic-like is that rapalogs do not directly cause cell death. The other reason is that
inhibition of mTORC1 alone suppresses negative feedback of PI3K/AKT and promotes
cell survival (30).
In order to improve the clinical application of mTOR inhibition, PI3K/mTOR dual
kinase inhibitors target the ATP binding pockets in the kinase domain of PI3K and
mTOR. The prototype compounds are ATP competitive PI3K inhibitors because PI3K
and mTOR share sequence similarities. Due to the potential high toxicity of
PI3K/mTOR dual inhibitors, inhibitors that are more specific to mTOR, such as
8

KU0063794 and AZD8055, have been developed. Some of them are in either phase I
or II clinical trials for cancer treatment (30).

1.3 Cell cycle regulation
The cell cycle is tightly controlled at multiple stages called cell cycle checkpoints
(Fig.3). Generally there are three checkpoints: the G1, G2/M and mitotic checkpoints.
At each checkpoint, cells determine whether the condition is optimal for the next phase.
Proteins

engaged

in

checkpoint

regulation

usually

undergo

a

cycle

of

synthesis/degradation and phosphorylation/de-phosphorylation. Cell cycle-specific
Cyclin-dependent kinases (CDKs) and Cyclins form complexes and are responsible for
cell cycle transition. The activity of CDKs, the most important enzymes in cell cycle
regulation, fluctuates during cell cycle. A set of kinases and phosphatases controls
CDKs activities through protein phosphorylation and de-phosphorylation, and the
expression levels of those kinases and phosphatases are usually regulated by different
ubiquitin proteasome systems under different conditions. CDKs activities also depend
on the dynamic changes of their partners Cyclins. Different Cyclins show their
abundance in different cell cycle phases through mRNA transcription control and
ubiquitin-mediated protein degradation. Here the whole cell cycle process will be
described shortly.
The G1 phase is a critical stage to decide whether a cell stays in the cell cycle or
enters a quiescent stage called the G0 phase. This point is known as the restriction
point (R) and it separates the G1 phase into two parts: the G1-pm (post-mitotic) and the
G1-ps (pre-S) phase. The restriction point is growth factor-dependent and a steady rate
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of mRNA and protein synthesis keeps the cell moving forward. Another G1 checkpoint
close to the S phase (the G1/S checkpoint) is a nutrient-sensing checkpoint. During
normal conditions, the CDK4/6-Cyclin D complex (first) and the CDK2-Cyclin E
complex (later) phosphorylate retinoblastoma protein (RB), which releases the E2F
family of transcription factors and triggers E2F-dependent transcription of cyclin E and
other genes required for S phase progression (31). Both Cyclin D and Cyclin E
expression is regulated by mTORC1-mediated protein synthesis (32). Proteins such as
PI3K and AMPK sense metabolic capability and mediate the mTORC1 activity. These
proteins link the status of growth factors, nutrition, amino acids, and energy to the G1
checkpoint, especially the late G1/S checkpoint, via control of Cyclins expression.
The S phase stands for the synthesis phase. The whole DNA replication process
is from the early G1phase to the end of the S phase. Before cells enter the S phase,
replication-related proteins keep recruited to the origins. Cells enter the S phase only
when everything is ready for DNA synthesis. Cells will not enter the G2/M phase if
replication is not complete.
The G2 phase is the rapid stage where cells make sure the division will go
smoothly in mitosis. The integrity of the genome will be checked and mitosis-related
proteins will be synthesized. The CDK1-Cyclin B complex mainly regulates G2/M
transition. The complex activity is controlled by the phosphorylation status of CDK1 and
the abundance of nuclear Cyclin B. In normal cells, Cyclin B expression is relatively low
in the G1 phase and reaches its peak in the end of the G2 phase. However, the CDK1Cyclin B complex is still inactive due to inhibitory phosphorylation of CDK1 at
Tyr15/Thr14 by WEE1/myelin transcription factor 1 (MYT1). Cells enter mitosis only
when increased cell division cycle 25 phosphatases (CDC25A/B/C) de-phosphorylate
10

these residues. This step also activates a positive feedback loop to ensure rapid
amplification of CDK1 activity: the CDK1-Cyclin B complex inhibits its inhibitors
WEE1/MYT1 and activates its activators CDC25 phosphatases through a protein called
polo-like kinase (PLK1) (33). In the late G2 phase, PLK1 is recruited to the centrosome
and promotes the recruitment of aurora kinase A which is responsible for PLK1
activation. The CDK1-Cyclin B1 complex phosphorylates Bora, the cofactor of aurora
kinase A, to facilitate PLK1 phosphorylation and activation by aurora kinase A at
Thr210. PLK1 is a positive regulator of CDC25C (34), and also triggers WEE1
degradation via the ubiquitin proteasome pathway (35-36). Thus, G2/M transition is
tightly controlled by the balance of CDC25 phosphatases and WEE1/MYT1 kinases
that function in the CDK1 de-phosphorylation and phosphorylation (35).
Mitosis is the phase to produce two identical daughter cells and it contains five
different stages. In prophase, chromatin condenses, nucleoli disappear and mitotic
spindles form. The nuclear membrane then breaks down and microtubules extend from
each end of the cell to the kinetochore, a protein around the centromere
(prometaphase). In metaphase, all chromosomes are perfectly oriented and line up
along the equator of the cell on the metaphase plate. Each pair of chromosomes (sister
chromatid pair) is then pulled to the opposite poles of the cell and separated into two
identical and independent chromosomes by mitotic spindles (anaphase). It is followed
by nuclear membrane and nucleoli reappearance, chromosome unwinding, and
cytokinesis that divides the cytoplasm into two identical cells (telophase).
The mitotic checkpoint, also known as the spindle assembly checkpoint (SAC),
controls metaphase-anaphase transition. Any single unattached kinetochore or a lack
of tension in the centromeric region during prometaphase can activate the checkpoint.
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During prometaphase, all SAC proteins and CDC20 are localized at kinetochores. The
checkpoint promotes assembly of the mitotic checkpoint complex, which contains
mitotic arrest deficient 2 (MAD2), budding uninhibited by benzimidazole 3(BUB3) and
BUB1-related protein kinase (BUBR1), at the kinetochore and further inhibits the
activity of CDC20. SAC proteins, including the mitotic checkpoint complex, remain
active until the formation of kinetochore microtubules.

After all chromosomes has

aligned, SAC proteins are removed and the E3 ubiquitin ligase anaphase-promoting
complex/cyclosome (APC/C) with its co-activator CDC20 degrades Cyclin B1 and
promotes mitotic exit after cell division (37). Daughter cells then enter the G1 phase
again.

1.4 DNA damage checkpoints: activation, recovery and adaptation
1.4.1 Activation
The cell cycle checkpoints in DNA damage response are not exactly the same
as checkpoints during normal cell cycle progression. The purpose of DNA damage
checkpoints is to ensure the competent state of DNA for duplication and division. It not
only provides time for cell-cycle specific repair, such as homologous recombination (HR)
repair in the S phase, but also prevents the trasition that may interfere normal
processing.
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Figure 3 The cell cycle transition
The diagram simply shows the cell cycle, checkpoints, and dynamic changes of the
CDK-Cyclin complexes.
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ATM and ATR signaling pathways control DNA damage checkpoint activation.
Different stimulants may activate different checkpoints and pathways. For example, IR
induces G2 arrest significantly but also activates G1/S and intra-S phase checkpoints
through ATM (first) and ATR (later) signaling pathways. Replication stress delays the
intra-S phase and G2/M transition generally through ATR activation. Once ATM and
ATR are activated, mainly ATM phosphorylates CHK2 at thy68 and ATR
phosphorylates CHK1 at Ser317/345. The following signaling cascade targets the
specific CDK-Cyclin complex and determines where cell cycle arrest.
ATM and ATR signaling pathways control DNA damage checkpoint activation.
Different stimulants may activate different checkpoints and pathways. For example, IR
induces G2 arrest significantly but also activates G1/S and intra-S phase checkpoints
through ATM (first) and ATR (later) signaling pathways. Replication stress delays the
intra-S phase and G2/M transition generally through ATR activation. Once ATM and
ATR are activated, mainly ATM phosphorylates CHK2 at thy68 and ATR
phosphorylates CHK1 at Ser317/345. The following signaling cascade targets the
specific CDK-Cyclin complex and determines where cell cycle arrest.
To control the G1/S checkpoint, the CDK2-Cyclin E complex and the CDK4/6Cyclin E complex are first locked in an inactive state through CDC25A degradation, and
they stay inactive through P53 stabilization. Phosphorylation of CDC25A at Ser123 by
CHK1 and CHK2 not only facilitates CDC25A degradation through the ubiquitinmediated proteolysis, but also regulates CDC25A interaction with the CDK2-Cyclin E
complex and the CDK4/6-Cyclin D complex (38). P53 is phosphorylted by ATM (at
Ser15), ATR (at Ser15), and CHK2 (at Ser20), and the phosphorylation leads to P53
stabilization by preventing its binding to mouse double minute 2 (MDM2), an E3
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ubiquitin-protein ligase. The stabilized P53 then drives gene transcription related to cell
cycle progression and programmed cell death, such as P21. As a negative cell cycle
regulator, P21 inhibits the CDK2-Cyclin E complex and the CDK4/6-Cyclin D complex,
further activating the G1/S checkpoint (39-41).
G2 arrest is predominant in cells treated with IR and the CDK1-Cycllin B1
complex plays a critical role. One mechanism to activate the G2/M checkpoint is
persistent inhibitory phosphorylation of CDK1. In response to DNA damage, WEE1
directly phosphorylates and inhibits CDK1 (42); meanwhile, nuclear CDC25A and
CDC25C decrease and reduce removel of phosphorylation from CDK1. 14-3-3
mediated degradation and cytoplasmic seqestration of CDC25A and CDC25C are
facilitated by their phosphorylation (Both CHK1 and CHK2 phosphorylate CDC25C at
Ser216 and CDC25A at Ser76) (6, 43). P21 interaction with the CDK1-Cyclin B1
complex

excludes

CDC25C

from

CDK1

and

also

maintains

the

inhibitory

phosphorylation of CDK1. Repression of PLK1 gene transcription by BRCA1 and CHK1
indirectly inhibits CDK1 activity via WEE1 and CDC25C (44). The other mechanism to
arrest cells in the G2 phase is the decrease of CCNB1 (encoding Cyclin B1) mRNA
level and 14-3-3σ-mediated cytoplasmic localization of Cyclin B1 (34). Another factor
aurora kinase B is phosphorylated by CHK1 at Ser311 and also contributes to
premature mitosis when cells face replication stress (45).
Unlike G1 and G2 checkpoints, the intra-S phase checkpoint is transient and
only affect part of the genome. In response to DNA damage, ATR and CHK1 directly
inhibit assembly of replication proteins, such as CDC7, CDC45, TOPBP1 and the
minichromosome maintenance complex component (MCM) complex, at the replication
fork and delay normal DNA synthesis (46-48). Degradataion of CDC25A through CHK1
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and CHK2 phosphorylation inhibits the CDK2-Cyclin A complex, the main complex for
S phase control (34). CHK1 also controls the activity of the CDK1-Cyclin A2 complex
through CDC25A, which is related to abnormal origin firing (49).
1.4.2 Recovery
After DNA damage has been repaired, cells arrested in specific phases
eventually restart their cell cycle progression. During checkpoint recovery, cells
reactivate the CDK-Cyclin complexes and reverse the checkpoint actions mainly
through inactivation of ATM and ATR signaling pathways and regulation of proteins
independent to DNA damage pathways. The process is still controlled by protein
synthesis/degradation and phosphorylation/dephosphorylation, but it is not exactly
opposite to checkpoint activation. For example, a E3 ubiquitin ligase called the
Skp1/Cullin/F-box protein (SCF) complex degrades different proteins during checkpoint
activation and recovery (50). Here molecules involved in checkpoint recovery are briefly
summarized here but the detail mechanisms are still not well known. Therefore, more
systemic approaches may need to be done.
Protein phosphatases dephosphorylated proteins in DNA damage pathways.
During the unperturbed S phase, CHK1 is continuously phosphorylated by ATR;
meanwhile, CHK1 dephosphorylated by protein phosphatase 2A (PP2A) prevents
phosphorylated CHK1 accumulation (38). Based on the function of PP2A in the balance
of phosphorylated CHK1, PP2A is likely to be one of the factors that control checkpoint
recovery. Another phosphatase called wild-type P53-induced phosphatase 1 (WIP1,
PP2Cδ) recognizes the p(S/T)Q motif which is specifically phosphorylated by ATM and
ATR. Many ATM and ATR downstream targets can also be targets of WIP1 (51).
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During G2/M checkpoint recovery, PLK1 seems to play an important role (51).
PLK1 phosphorylates WEE1 and Claspin for their degradation. PLK1 also
phosphorylates CHK2 and inhibits CHK2 kinase activity. Furthermore, during mitosis
reentry, PLK1 directly interacts with P53-binding protein 1 (53BP1) to inactivate the
checkpoint signaling (52). PLK1 promotes CDC25C translocation to nucleus to activate
CDK1 activity. However, how PLK1 is regulated during checkpoint recovery is not well
known. One possible regulation is through aurora kinase A, but more detail
mechanisms should be studied.
Other proteins, such as Artemis (the phosphorylated form regulates the CDKCyclin complexes) and forkhead box M1 (FOXM1, a transcription factor required for
G2/M checkpoint recovery), also involve in checkpoint recovery (53). In general, there
is still a gap between checkpoint activation and checkpoint recovery, and the process is
important for cell survival.
1.4.3 Adaptation
Checkpoint adaptation is first discovered in yeast. This is the phenomenon that
cells escape from long-term cell cycle arrest in spite of the presence of DNA damage.
Cells usually maintain a basal level of the CDK-Cyclin complexes during DNA damageinduced cell cycle arrest and it provides capabilities to recover or escape from cell cycle
arrest. Similar to checkpoint recovery, the process is controlled by ATM and ATR
signaling pathways and pathways independent to DNA damage signaling (54). The
difference is persisted DNA damage in checkpoint adaptation but how cells ignore
damage is still not clear. If checkpoint adaptation happens in cells with other checkpoint
defects, cells will keep proliferation and it may result in genomic instability.
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1.5 Mitotic catastrophe as a mechanism to maintain genomic stability
Genome integrity has a significate impact on cell survival. In order to maintain
genomic stability, cells have developed a network, the DNA damage response, to
detect and repair DNA damage with cell cycle arrest. Inhibition of proteins in the
network affects normal cell cycle progression, including inappropriate DNA synthesis in
the S phase and abnormal cell division in mitosis. For example, deregulated CDK
activity increases late origins firing inappropriately in the S phase. WEE1 depletion
induces DNA damage in newly replicated DNA (48). If those damages are not repaired,
cells may undergo cell cycle arrest, programmed cell death, or keep moving to the next
cell cycle phase with those damages. The persisted damages will further cause
genomic instability, which may promote cancer formation.
Mitotic catastrophe results from premature or inappropriate entry of cells into
mitosis. It occurs either during or shortly after dysregulated mitosis. The aberrant
mitosis is usually induced by various agents in the presence of genetic defects, such as
impaired DNA repair machineries, insufficient checkpoint functions, or mitosis defects.
The consequence of mitotic catastrophe can be apoptosis, necrosis, or senescence. It
depends on the molecular profiles of cells and the duration of mitotic arrest (55-56). For
example, the absence of P53 in CHK2-depleted cells abrogates the availability of
caspases and drives cells from mitotic catastrophe to necrosis, while the presence of
functional P53 in CHK2-depleted cells facilitates apoptosis (57). Cells arrested in
mitosis for a short period of time showed variable fates, while cells blocked in mitosis
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for longer time died after exiting mitosis (58). The characteristics of mitotic catastrophe
suggest that it is heterogeneous and involves several mechanisms.
Mitotic catastrophe is associated with chromosomal breaks, deficient nuclear
division (karyokinesis), premature condensation of chromosome, and the formation of
giant cells with multiple micronuclei, some of which are also shown in apoptosis and
necrosis. The morphological changes of apoptosis include cell shrinkage, chromatin
condensation (pyknosis), nuclear fragmentation (karyorrhexis), extensive membrane
blebbing, formation of apoptotic bodies (budding) and phagocytosis (59). Necrosis
involves cell and organelle swelling, cytoplasmic vacuoles formation, chromatin
condensation and nuclear membrane dilatation, plasma membrane disruption and
presence of inflammatory reaction (60). Given mitotic catastrophe as a prelude to
apoptosis, necrosis, or senescence, it is difficult to define mitotic catastrophe simply
based on the morphological criteria.
Many proteins have been identified to link aberrant mitosis, mitotic catastrophe
and cell death together. They include SAC proteins, CDK1, P53, BCL-2 family
members, and Death Domain (DD) super-family members, such as Caspases. The
MCC component BUBR1 directly interacts and disrupts the formation of the Caspase 2based platform at the kinetochore, and further inhibits apoptosis during mitosis (61). On
the contrary, Caspases have been shown to cleave and inactivate BUBR1 (62). CDK1mediated phosphorylation of the BCL-2 family, Caspase 2, 8 and 9 prevents apoptosis
during mitosis (56, 63). Phosphorylation of P53 by SAC proteins, such as PLK1,
regulates the transcriptional activity of P53 and controls cell death. Those molecules
tightly work as a network to mediate mitosis and cell fates after mitotic entry.
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The function of mitotic catastrophe links to genomic stability. Cells with mitotic
catastrophe suppression may generate aneuploid cells through multipolar or abnormal
bipolar divisions, or generate polyploid cells through mitotic slippage (cells exit mitosis
without division through unspecific degradation of Cyclin B1 in spite of the SAC
signaling (64)). Those abnormal cells are usually arrested in the G1 phase or undergo
mitotic catastrophe in the next M phase. However, if cells bypass those barriers, cells
may increase genomic instability, a driving force of certain human diseases such as
cancer. Therefore, mitotic catastrophe can be a strategy to prevent or treat human
diseases.

1.6 Drugs related to DNA damage response
The DNA damage response machinery is linked with human diseases. It forms a
biological barrier against the development human diseases, and in the meanwhile, the
high demand of the DDR machinery in certain types of cells provides a therapeutic
window. Here two drugs in this study will be only briefly introduced.
1.6.1 PARP inhibitors
Poly(ADP-ribose) polymerase (PARP) involves in various repair machineries
and fork reversal. In response to ssDNA breaks, PARP can directly bind DNA, and the
polymerization of ADP-ribose usually occurs immediately to provide a platform for other
damage response proteins. CHK1 activation is also enhanced by poly(ADP-ribose),
which suggests that PARP inhibition may increase replication stress by diminishing the
CHK1 activity. PARP inhibition causes synthetic lethality with HR repair defects, and
the effect results from the increase of unrepaired primary lesions processed into DSBs
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which require Rad51-dependent HR repair. The most famous example is PARP
inhibitors in Brca1- or Braca2-mutated cancer treatment (65-66). Three randomized
phase III trials of a PARP inhibitor olaparib in Brca-mutated breast cancer have been
conducted and another PARP inhibitor, rucaparib, has been approved by US Food and
Drug Administration (FDA) for advanced ovarian cancer treatment (46). BMN 673, one
of the PARP inhibitors in my study, shares many biochemical profiles with early
generations of PARP inhibitors, such as olaparib and rucaparib, but BMN 673 achieves
its cytotoxic effect with much lower concentration. Recent studies have shown that the
cytotoxicity of the PARP inhibitor is correlated with its ability to trap PARP-DNA
complexes instead of the catalytic inhibitory property (67-69). It became the rationale to
test BMN 673 in my study.
1.6.2 WEE1 inhibitors
Both WEE1 and CHK1 involve in the G2/M checkpoint control. WEE1 inhibition
enhances the CDK activity and induces premature mitotic entry. Similar to CHK1
inhibition, drug-based WEE1 inhibition also leads to unscheduled origin firing, the
shortage of nucleotides, the decrease of fork progression speed, massive DSBs and
eventually cell death (46). Cells without functional P53 are usually more sensitive to the
G2/M checkpoint abrogation because they lack the P53-dependent G1 checkpoint and
therefore depend on the G2/M checkpoint for DNA damage repair (42). Several phase
II clinical trials have tested MK-1775 (AZD-1775), a selective ATP-competitive WEE1
kinase inhibitor, in P53-mutant cancer patients and the trials are still ongoing (47).
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SIGNIFICANCE OF THE STUDY

Developed a systemically approach to analyze RPPA data and simplified the complex
biomedical question using a non-biased mathematical modeling

Identified that mTORC1 controlled a transcriptional program of mitotic entry through
epigenetic regulation of mitosis-related genes during checkpoint recovery

Linked nutrient status to G2/M checkpoint recovery from irradiation

Provide a therapeutic strategy using the WEE1 inhibitor for TSC patients
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CHAPTER 2
Materials and Methods

2.1 Cell lines and culture
Human U2OS cells were grown in McCoy’s 5A medium with 10% fetal bovine
serum (FBS, ThermoFisher Scientific). HEK 293T (human embryonic kidney epithelial)
cells, HCT-116 (human colorectal carcinoma) cells, MEF (mouse embryonic fibroblast)
cells and ELT3-V3/T3 (Eker rat uterine leiomyoma, from Dr. Jane Yu’s lab) cells were
in DMEM medium plus 10% FBS and 1x penicillin-streptomycin (15140-122, Gibco, Life
technologies). HCT116 mTOR kinase-dead conditional knock-in (D2338A-cKI) cells
were in RPMI-1640 medium with 2mM L-glutamine, 25mM sodium bicarbonate, and
10% FBS as Horizon suggested. Cells were all kept in the 37°C humid incubator with
5% CO2.
To make AA+ medium, we added 1X MEM amino acids (Invitrogen), 1X MEM
non-essential amino acids (Invitrogen) and 1X L-glutamine (Invitrogen) into amino-acid
free (AA-) RPMI-1640 medium with 10% FBS. We then mixed AA- medium (0%) with
AA+ medium (100%) to make 0.01% to 10% AA medium.
To generate the rapamycin-resistant cell line ELT3-V3R, most of ELT3-V3 cells
were killed with 10nM rapamycin and then the rest of cells were cultured with low-dose
to high-dose rapamycin for a period of time.
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2.2 Ionizing radiation
Ionizing radiation (IR) was induced by the high-voltage X-ray tubes (RS-2000
Biological Research Irradiator, Red Source Technologies). MEF cells were irradiated
with 15Gy and the rest of the cells were irradiated with 7Gy. We treated cells with 2μM
paclitaxel after IR to arrest cells in mitotic phase (HCT116: 2 hours after IR; U2OS: 6
hours after IR; TSC2: immediately after IR).

2.3 Antibodies, plasmids and reagents
The purpose of rapamycin (0.02nM or 20nM, Sigma-Aldrich), KU0063794 (1μM,
Selleckchem) and AZD8055 (1μM, Selleckchem) is to inhibit mTOR activity. MK2206
(0.1μM, AKT inhibitor), MK1775 (10nM to 0.5μM, Wee1 inhibitor), BMN 673 (20nM or
50nM, PARP inhibitor), and olaparib (5μM, PARP inhibitor) were purchased from
Selleckchem. Paclitaxel (2μM) was from Sigma-Aldrich.
Myc-tagged mTOR-WT (wild type) plasmid, Myc-tagged mTOR-KD (kinase dead)
plasmid, mTOR, and control shRNA were provided by Dr. Dos Sarbassov (70). ATM,
ATR, mTOR, and KDM4B smart-pool siRNA, and control siRNA (ON-TARGETplus
Non-targeting control siRNAs #1) were purchased from GE Dharmacon. Individual
mTOR

(#1:

5'-GGCCAUAGCUAGCCUCAUA-3'

and

#2:

5'-

CAAAGGACUUCGCCCAUAA-3'), Raptor (5'-GGACAACGGCCACAAGUAC-3'), Rictor
(5'-ACUUGUGAAGAAUCGUAUC-3'), and control (Mission siRNA universal negative
control #1) siRNAs were synthesized from Sigma-Aldrich (71-73).

24

Rabbit anti-mTOR antibody, rabbit anti-S6K antibody, rabbit anti-S6 antibody,
rabbit anti-p-S6 (Ser235/236) antibody, rabbit anti-AKT antibody, rabbit anti-p-AKT
(Ser473) antibody, rabbit anti-KDM4B antibody, rabbit anti-Cyclin B1 antibody, rabbit
anti-p-H3 (Ser10), rabbit anti-ATM antibody, mouse anti-CHK1antibody, rabbit anti-pCHK1 (Ser345) antibody, mouse anti-CHK2 antibody, rabbit anti-p-CHK2 (Thr68)
antibody, rabbit anti-H2AX antibody, and rabbit anti-γ-H2AX (Ser139) antibody were
purchased from cell signaling technology. ChIP grade rabbit anti-mTOR antibody was
from Abcam. Mouse anti-β-Actin antibody and mouse anti-α-Tubulin antibody were
from Sigma-Aldrich. Mouse anti-Cytochrome c antibody was from BD Biosciences.
Antibodies from Bethyl Laboratories were rabbit anti-Raptor antibody and rabbit antiKDM4B antibody. Reagents from Santa Cruz Biotech include goat anti-Rictor antibody,
mouse anti-PLK1 antibody, goat anti-ATR antibody, mouse anti-MYC antibody, mouse
anti-GADPH antibody, all HRP-conjugated secondary antibodies, and normal IgG. Antiannexin-V Alexa Fluor 647 conjugated antibody and Alexa Fluor fluorescent dyes were
from Life Technologies.

2.4 Cell viability, cell proliferation assay, apoptosis assay and 3D culture
Cell viability was examined with MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5dephenyltetrazolium bromide) assay. First, we plated 250 or 500 cells/well in 96-well
plates one day before drug treatment and incubated cells with drugs for at least four
days. After treatment, cells were incubated with 20ul 2μg/μl MTT (Life technologies) at
37°C for 3 hours. DMSO (dimethyl sulfoxide, Fisher Scientific) was added to dissolve
blue formazan crystals and the absorbance values were read in the plate reader (Bio25

Tek). To evaluate cell apoptosis after drug treatment, the percentage of apoptotic cells
was determined by detection of annexin V-bound translocated membrane component
by flow cytometry and the protocol was provided by the manufacturer (Life
Technologies). For 3D cell culture, we coated 96-well plates with 30μl/well Matrigel
(Fisher Scientific) and seeded 1000cells/100μl medium in each well. Two days after
seeding cells, we changed new medium with/without drugs and incubated cells for
another three days. 10μl of PrestoBlue cell viability reagent (Invitrogen) was directly
added into each well for 10 minutes at 37°C. Fluorescent values were measured with
530/25 and 590/35 nm as excitation and emission wavelength in Synergy H1 MultiMode Reader (BioTek). For 3D culture representative photos, we seeded 4000
cells/400μl medium in each Matrigel pre-coated 8-well chamber slides and cultured
cells for 10 days. 0.2μM MK1775 was added on Day 3 and the medium ± 0.2μM
MK1775 was changed every three days. The photos were taken with Olympus IX71
microscope (NORTH Campus Flow Cytometry and Cellular Imaging Core Facility, MD
Anderson Cancer Center) and analyzed by Image J. To determine the percentage of
apoptotic cells after drug treatment, we followed the protocol provided by the
manufacturer (Life Technologies) and detected annexin V-Alexa Fluor 647-positive
cells as apoptotic cells on Gallios Flow Cytometer.

2.5 Cell cycle analysis and mitotic entry by flow cytometry
Different biomarkers were used to measure cell populations in different cell
cycle. Propidium iodide (PI, excitation source 488nm argon ion laser) is to assess cell
cycle by quantitation of DNA content. Phosphorylated histone H3 on Ser10 is the
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mitosis phase marker. Cells were harvested and fixed in 70% alcohol at -20°C for at
least 2 hours before stained with PI, fluorophore-conjugated antibodies against
phosphorylated histone H3. For PI staining, we incubated cells with PI solution
(10μg/ml PI, 1.25μg/ml RNase A and 0.05% Triton X) for at least 10 minutes. To detect
mitotic cells, cells were incubated in permeabilization buffer (0.25% Triton X100 in PBS)
on ice for 10 minutes and stained with phosphorylated histone H3-Ser10-Alexa 647
antibody at room temperature for at least 3 hours. All cell cycle progression data were
acquired on Gallios Flow Cytometer (Beckman Coulter, Inc.) at the University of Texas
MD Anderson Cancer Center FACS core facility and were analyzed by FlowJo V10
software (FlowJo, LLC).

2.6 Western blotting
To detect total protein expression, cells were lysed in urea lysis buffer (8M urea,
50mM Tris-HCl pH 7.5 and 150mM β-mercaptoethanol). We separated nuclear and
non-nuclear fractions using Dounce homogenizer with Nori buffer (20mM HEPES pH
7.0, 10mM KCl, 2mM MgCl2, 0.5% NP-40 and 1X protease inhibitor cocktails) and urea
buffer. Signals were detected with Amersham Enhanced Chemilumminescence (ECL)
Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences).

2.7 Immunofluorescence staining
Cells on cover slips were fixed with 4% paraformaldehyde solution (Santa Cruz
Biotechnology) at room temperature for 10 minutes, and blocked with 3% BSA in 0.1%
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Triton X-100-PBS for 30 minutes. Cells were incubated in primary antibody at room
temperature for 2 hours and in secondary antibody at room temperature for 2 hours.
Cells may be counterstained with DAPI (4’, 6-diamidino-2-phenylindole) before
mounting. Photos were taken with Olympus IX81 microscope or FV1000 laser confocal
microscope (NORTH Campus Flow Cytometry and Cellular Imaging Core Facility, MD
Anderson Cancer Center), and data was analyzed by Image J or FV10-ASW 4.2
Viewer (Olympus).

2.8 Single-cell gel electrophoresis (comet assay)
U2OS cells were treated with IR and DNA damage was detected by alkaline
comet assay following the CometAssay Reagent Kit instruction (Trevigen). After cells
were stained with SYBR Green, the photos were taken with Olympus IX81 microscope
(NORTH Campus Flow Cytometry and Cellular Imaging Core Facility, MD Anderson
Cancer Center) and data was analyzed by CometScore 1.6 (TriTek Corp.).

2.9 RNA isolation and qRT-PCR
Complementary DNA was generated from RNA using TRIzol reagent and the
SuperScript III kit (Invitrogen). The quantitative polymerase chain reaction (qPCR)
reactions were performed using Power SYBR Green PCR Master Mix kit on the ViiA7
Real-Time PCR System (Invitrogen). qPCR primers were designed to span exon–intron
boundaries of respective genes, ensuring the results were not affected by genomic
DNA contamination. The sequences of qPCR primers are listed in Table 1.
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Oligonucleotides for qPCR
Gene name
F
PLK1
R
F
CCNB1
R
F
ACTB
R

Primer Sequence (5’-3’)
GGCAACCTTTTCCTGAATGA
TCCCACACAGGGTCTTCTTC
TTGGGGACATTGGTAACAAAGTC
ATAGGCTCAGGCGAAAGTTTTT
GAGCACAGAGCCTCGCCTTT
TCATCATCCATGGTGAGCTG

Product
103 bp
226 bp
113 bp

Oligonucleotides for ChIP-qPCR
Gene
name
PLK1

Primer Sequence (5’-3’)

Promoter region

F GTAACGTTCCCAGCGCCG
-60 ~ +63 bp
R CAGCTTCCCTGCAGTCACTG
F CCAATAAGGAGGGAGCAGTG +86 ~ +187 bp
CCNB1
R GGACCTACACCCAGCAGAAA
F: forward; R: reverse
Table 1 Oligonucleotides used for qPCR and ChIP-qPCR
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2.10 Chromatin immunoprecipitation (ChIP)-qPCR assay
We performed ChIP-qPCR assay following the EZ-ChIP kit instruction
(Millipore). U2OS cells were incubated in the growth medium with 1% formaldehyde for
10 minutes and the crosslink reaction was stopped with 0.125M Glycine for 5 minutes
at RT. We suspended cells in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH
6.5, 1X protease inhibitor cocktail) and sheared DNA to around 600 base pairs in length
by 60 Sonic Dismembrator (Fisher Scientific). For each ChIP reaction, we added 900ul
Dilution Buffer into 100ul of chromatin and incubated chromatin with Protein G agarose
beads at 4°C for 1 hour. After centrifugation, 10ul of the supernatant was removed as
Input and the rest supernatant was incubated with 1-2μg antibodies overnight and
Protein G agarose beads for 1 hour. The antibodies for ChIP-qPCR were rabbit antiKDM4B (Cell Siganling), ChIP-Grade rabbit anti-H3-trimethyl K9 (H3K9me3, Abcam),
rabbit anti-B-myb (Bethyl) antibodies and rabbit normal IgG (Santa Cruz).
After IP samples were washed by buffers containing different concentrations of
salts, protein-DNA complexes were eluted and their crosslinks were reversed in IP
samples and also Input. DNA was purified in 50ul Elution Buffer for subsequent qPCR
analysis. We added 23ul of qPCR mix containing 400nM of primers and Power SYBR
Green PCR Master Mix (Life Technologies) to 2μl of purified DNA for one reaction. The
qPCR reactions were performed in the ViiA7 Real-Time PCR System (Invitrogen) and
the results of ChIP-samples were normalized to Input individually in each set of
samples. The sequences of CHIP-qPCR primers were listed in Table 1.
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2.11 Dual-luciferase reporter assay
U2OS cells were cultured in 60 mm plates and siRNA oligonucleotides were
transfected. One day after siRNA transfection, cells were transfected again with
indicated luciferase (Luc) expressing plasmids and then were split into 6-well plates.
One day after Luc transfection, cells were given 7Gy IR and cultured for indicated time
points for the assay. We measured PLK1-Luc or Cyclin B1-Luc levels in 96-well plates
using Dual-luciferase Reporter Assay kit (Promega) and the manufacturer’s instructions
in FLUOstar Omega microplate reader (BMG Labtech) were followed. All samples were
normalized to Renilla-Luc activity.

2.12 Reverse phase protein array (RPPA)
We mainly followed the lysate preparation protocol provided by RPPA Core
Facility in MD Anderson Cancer Center. U2OS and HCT116 cells were seeded in 6well plates and the final cell amounts in each sample fitted the minimum requirement of
RPPA. Cells were irradiated with 7Gy and then were incubated with 2μM paclitaxel at
indicated time points. We washed the cells with PBS twice before lysed the cells with
lysis buffer (1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2,
1mM EGTA, 100mM NaF, 10mM sodium pyrophosphate, 1mM Na3VO4, 10% glycerol,
protease and phosphatase inhibitors) on ice for 20 minutes. Cells were collected into
tubes and spun down at 14,000 rpm at 4°C for 10 minutes. Protein concentration in
supernatant was determined and was adjusted to 1-1.5 μg/μl. Cell lysate was mixed
with 4x SDS sample buffer without bromophenol blue and boiled for 5 minutes.
Samples were stored in -80°C before RPPA processing. The RPPA data was
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normalized by RPPA Core Facility and was further analyzed with the statistical
programming language R, Ingenuity Pathway Analysis (IPA, QIAGEN) and MATLAB
(MathWorks). The files “bfs_augmentpath.m” and “show_ff_max_flow.m” were written
based on the Ford-Fulkerson algorithm and breadth-first search, but we don’t claim the
authorship (Fig. 4). The files “output_data.m” and “save_data_build.m” were used to
export and save data to Microsoft Excel (Microsoft). We used the file “main.m” to
control all other MATLAB files and to generate the array for further calculation (Fig. 5).

2.13 Animal studies
All animal works were performed with protocols approved by the MD Anderson
Animal Care and Use Committee. 2 x 106 ELT3-V3/T3-luciferase cells were injected
subcutaneously into the bilateral posterior flanks of female CB17-SCID mice (Charles
River Laboratories). Five weeks after cell injection, mice bearing 100-150mm3 tumors
were randomized into different groups (n=6) (74). Mice were treated with MK1775
vehicle or 60mg/kg MK1775 (in 0.5% methylcellulose) once every two days plus BMN
673 vehicle or 0.33mg/kg BMN 673 (in 5% dimethylacetamide and 5% Solutol and 85%
PBS) once daily until tumor size in any group reached 1500mm3 (three weeks in total)
(67, 75). Body weight was measured once a week as the parameter of toxicity. Tumor
volume using the formula (length x width2)/2 was measured twice a week. We also
used bioluminescence imaging to follow tumor size (IVIS 200, MDACC Small Animal
Imaging Facility). At the end point, tumor weight was measured when mice were
sacrificed.
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Figure 4 The Ford-Fulkerson algorithm and breadth-first search in MATLAB
The graph on the top was an example how the Ford-Fulkerson algorithm worked and how we
defined the terms we used in our programs. The flow charts demonstrated how we found

potential targets and pathways in MATLAB by the Ford-Fulkerson algorithm and
breadth-first search.
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Figure 5 The flow chart for the main program written in MATLAB
The flow chart demonstrated how we used the main program “main.m” to control
subroutines (all other “.m” files) in MATLAB.
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2.14 Statistics
All graphs were shown as mean values ± SD (standard deviation) or SEM
(standard error of the mean). Statistical significant was determined by two-tailed,
unpaired Student’s t-test in software Graphpad Prism 6. The statistical significance was
defined as p value under 0.05.
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CHAPTER 3
The Role of mTORC1 in Checkpoint Recovery

DNA damage response has been studied for decades, but how cells recover
from checkpoint activation is not well known. In order to systematically understand the
molecular basis of checkpoint termination, we performed a multidisciplinary study by
combining reverse phase protein array (RPPA) data, molecular biology and
mathematical modeling to identify molecules required for DNA damage checkpoint
recovery. mTORC1 played an essential role to regulate mitotic entry after irradiation. It
controlled a transcriptional program of checkpoint recovery through regulating histone
lysine demethylase KDM4B and further epigenetically regulated mitosis-related genes
including CCNB1 (encoding Cyclin B1) and PLK1 (encoding PLK1). Given TSC2depleted cells with faster checkpoint recovery, we tested the effect of the WEE1
inhibitor combined with the PARP inhibitor both in vitro and in vivo. The combination
treatment induced stronger mitotic catastrophe in TSC2-depleted cells and the WEE1
inhibitor itself showed its effect in the mouse model. Thus, we provided a therapeutic
approach for TSC patients with TSC2 mutation.

3.1 mTOR is the candidate to mediate DNA damage checkpoint recovery
In order to discover potential molecules which generally control G2/M checkpoint
recovery after ionizing radiation (IR), we performed the reverse phase protein array
36

(RPPA) in two p53-proficient cell lines (U2OS and HCT116) and developed a series of
methods to analyze data (Fig. 6). Basically, we treated cells with IR and then arrested
cells in the mitosis phase with paclitaxel to ensure that each cell enter the mitosis
phase only once. We aligned 6 time points in two cell lines during the process of
checkpoint recovery based on cell cycle and mitotic entry analysis in order to compare
protein expression in parallel later (Fig. 7). After we got RPPA data, the expression
levels of each protein at different time points were first normalized by the level at time 0
for each cell line. Simple linear models were then constructed to predict normalized
expression of each protein in U2OS by respective expression in HCT116. Regression
equations with a false discovery rate (FDR) < 0.3 were considered significant and the
correlation coefficients (r) between 0.7 and 1 were in terms of strong positive linear
relationship. Based on the criteria above, we selected 84 molecules and the heat map
showed that the protein expression trends during recovery in U2OS and HCT116 were
similar (Fig. 8). We then uploaded 84 molecules in Ingenuity Pathway Analysis (IPA) for
canonical pathway and network analysis (76). The top ten canonical pathways based
on p-value included pathways related to cancers and the PI3K signaling network (Fig.
9). The top two networks with the score higher than 20 involved cellular response to IR,
including cell death and survival, cellular growth and proliferation, and cancer (Table 2).
To identify key molecules which regulate checkpoint recovery after IR, we merged
those two IPA networks and applied the Ford-Fulkerson algorithm to calculate the
maximum signals received by CCNB1 or CCND1 (the genes encoding Cyclin B1 or
Cyclin D1, two proteins that control cell cycle progression). We chose ten sets of
parameters to represent relationships between two molecules in the IPA network
(interaction, direct control and indirect control) and calculated total numbers of each
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protein shown as the upstream regulator (source) or in the pathways with maximum
signals to CCNB1 or CCND1. The scatter plot showed that MTOR, EGFR, and AR (the
genes encoding mTOR, EGFR, and androgen receptor) were the top three candidates
when we combined results of CCNB1 and CCND1 groups. We compared our results to
the IPA upstream regulator analysis result which has no specific downstream target,
MTOR, EGFR, and AR were the only three molecules shown in the three groups (Fig.
10). Given mTOR belonging to the same family as ATM and ATR, we chose mTOR as
our target for further studies.
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Figure 6 The flow chart for RPPA data analysis
The flow chart demonstrated the process how we identified candidates related to DNA
damage recovery from RPPA results
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Figure 7 The first step for RPPA data analysis-cell cycle alignment
RPPA was performed in U2OS cells and HCT116 cells. Cells were irradiated with IR
7Gy and then were trapped in the mitotic phase using 2μM paclitaxel for a period of
time. Six time points were chosen based on cell cycle patterns and mitotic entry
analysis. The percentage of mitotic cells defined as phospho-Histone H3 (p-H3)
positive cells was shown in each representative graph.
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Figure 8 The second step for RPPA data analysis-linear regression and
correlation
We used the linear regression slope of each protein in U2OS cells to predict the same
protein expression in HCT116 cells and calculate correlations between two cell lines.
Regression equations with a FDR value < 0.3 were considered significant in terms of
linear relationship and within those proteins, we only chose proteins with correlation r
value > +0.7 for IPA network analysis. The names in red were two proteins we used as
the downstream targets for calculation.
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Network functions
Cell death and survival,
cancer, organismal injury
and abnormalities

Cell death and survival,
cellular development,
cellular growth and
proliferation

Molecules
AKT1,AR,BAD,BCL2L1,BCL2L11,BEC
N1,CAV1,CDKN1A,CDKN1B,CHEK1,
EGFR,ERBB2,ERBB3,FOXM1,
FOXO3, MAP2K1,MET,MSH6,MTOR,
PARP1,PCNA,PIK3CA,PIK3R1,RAF1,
RB1,RICTOR,RPS6,RPS6KA1,SRC,
STMN1,YAP1,YBX1,YWHAB,YWHAE,
YWHAZ
BAK1,BID,BRCA2,CASP7,CCNB1,
CCND1,CDH1,CTNNB1,DVL3,
EIF4EBP1,FASN,GAPDH,LCK,
MAPK1,MAPK8,MAPK14,NFKB1,
PDCD4,PECAM1,PRKCD,RPTOR,
SETD2,SMAD4,SNAI2,SRSF1

Score Molecules
79
35

47

25

Table 2: Top two network functions and their molecules identified from IPA
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Figure 9 Top ten canonical pathways identified from IPA
Top ten significant canonical pathways enriched with molecules from our screened
RPPA dataset were calculated in Ingenuity Pathway Analysis (IPA). The ratio indicated
how many molecules in our RPPA dataset were associated with the specific pathway.
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Figure 10 The final step for RPPA data analysis-the IPA network and the FordFulkerson algorithm
We generated the network in IPA and the scatter plot represented the calculation result
based on the Ford-Fulkerson algorithm. The potential upstream targets (words in red)
came from comparison between our calculation results and IPA upstream regulator
analysis. FDR: false discovery rate.
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3.2 mTOR regulates mitotic entry during recovery from IR-induced G2 arrest
We depleted mTOR by siRNA oligos in U2OS cells and treated cells with
ionizing radiation (IR, 7Gy). In control groups, cell cycle progression was arrested in the
G2/M phase 16 hours after IR and was recovered gradually 40 hours after IR. Cells
with mTOR depletion showed impairment of cell cycle recovery after IR and more than
half of cells were still in the G2/M phase (Fig. 11). We further measured the
accumulations of mitotic cells trapped by paclitaxel after IR using p-H3 (S10) staining
(Fig. 12). Without IR treatment, the percentages of mitotic cells were relatively similar in
both control and mTOR-depleted groups. During recovery from irradiation, the mitotic
cells dropped to almost zero first and then increased. Cells with mTOR depletion
showed the defect in mitotic entry and statistical analysis demonstrated the significance
both 24 hours and 32 hours after IR. The similarity of mitotic cell percentages in both
control and mTOR-depleted groups treated with paclitaxel alone indicated the delay of
mitotic entry in mTOR-depleted cells was caused by IR but not paclitaxel. We also
detected expression of cell cycle regulators, including Polo-Like Kinase 1 (PLK1),
Cyclin B1 and p-H3, and those protein levels were lower in mTOR-depleted cells
compared to control cells at each time point after IR (Fig. 13). The results suggested
that mTOR played a role in G2/M checkpoint recovery after IR, and the phenomenon in
U2OS cells also found in HCT116 cells (Fig. 14) indicated the function of mTOR was
not cell-type specific.
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Figure 11 mTOR regulated G2/M checkpoint recovery-cell cycle analysis
U2OS cells with or without mTOR depletion were collected at different time points after
IR (7Gy) for cell cycle analysis and the percentages of G2/M cells were presented in
the bar graph. The depletion of mTOR was detected by western blot. Mock: cells incubated
with only the transfection reagent; si-ctrl and si-mTOR: cells transfected with non-target
control siRNA and mTOR siRNA; ctrl: control; error bars represent mean ± SEM; n = 3
independent experiments; * p<0.05
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Figure 12 mTOR regulated G2/M checkpoint recovery-mitotic entry analysis
U2OS cells were treated with IR (7Gy) and 2μM paclitaxel following siRNA transfection.
Cells were stained with PI and p-H3 for mitotic entry analysis. The numbers in
representative figures indicated the percentages of mitotic cells, which were defined as
positive phospho-Histone H3 (p-H3 (+)) cells with 4N DNA contents. The ratio of mitotic
cells was presented as the percentage of mitotic cells in the si-ctrl or si-mTOR group
relative to the percentage of mitotic cells in the mock group at each time point. Mock:
cells incubated with only the transfection reagent; si-ctrl and si-mTOR: cells transfected
with non-target control siRNA and mTOR siRNA; ctrl: control; error bars represent
mean ± SEM; n = 3 independent experiments; * p<0.05
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Figure 13 mTOR regulated G2/M checkpoint recovery-western blot
mTOR was depleted by either siRNA pool oligos (si-mTOR) or two individual siRNA
oligos (si-mTOR #1 and #2) in U2OS cells. Protein samples at different time points
were collected for immunoblot. Actin was an internal control.
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Figure 14 The function of mTOR in G2/M checkpoint recovery is not cell-type
specific
We depleted mTOR by either shRNA or siRNA in HCT116 cells and treated cells with
IR (7Gy) plus 2μM paclitaxel for mitotic entry analysis and immunoblot. si-ctrl and simTOR: cells transfected with non-target control siRNA and mTOR siRNA; ctrl: control;
error bars represent mean ± SEM; n = 3 independent experiments; * p<0.05
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3.3 The mTORC1 kinase activity is required for mitotic entry after irradiation
We further tested whether mTOR in mitotic entry regulation after IR required the
integrity of the mTOR complex and the kinase activity. First, we treated U2OS cells with
rapamycin (mTORC1 inhibition) or KU0063794 (mTORC1/mTORC2 dual inhibition)
before irradiation and paclitaxel. The percentages of mitotic cells in both drug-treated
groups were less than the percentage in the DMSO group, but the difference was more
dramatic during checkpoint recovery (Fig. 15). The result suggested that the function of
mTOR in checkpoint recovery was through the complex and its kinase activity.
To clarify the role of the mTOR kinase activity in checkpoint recovery, we used
D2338A-cKI HCT116 cells with knock-in of kinase-dead mutation (D2338A) in one
allele and conditional knock-in of mutation in the other allele. After Cre-Lox
recombination (+Cre), D2338A-cKI cells produced only kinase-dead mTOR (Fig. 16).
We treated the cells with IR and paclitaxel as we did before. The percentage of mitotic
cells and the levels of PLK1, Cyclin B1 and p-H3 during checkpoint recovery were
positively correlated with the mTOR kinase activity (Fig. 17). It suggested that mTOR
kinase activity was important for cell cycle recovery regulation.
We next depleted Raptor and Rictor by siRNA oligos in U2OS cells to see
whether mTORC1 or mTORC2 involved in the recovery process. Raptor-depleted cells
showed similar recovery defects to mTOR-depleted cells. The percentage of p-H3
positive cells during recovery from irradiation decreased in cells with Raptor or mTOR
depletion, but not in cells with Rictor depletion. Reduced levels of PLK1 and p-H3 were
only shown in Raptor-depleted cells during the recovery process (Fig. 18). The results
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indicated that mTORC1 but not mTORC2 was required in the recovery process of
cellular response to irradiation.
We further confirmed the results by depletion of amino acid which controls the
activation of mTORC1. In cells without IR treatment, amino acids withdrawal from 10%
to 0.01% decreased mitotic cell population. After IR and paclitaxel treatment, the
percentages of mitotic cells in the condition of amino acids withdrawal dropped more
compared to cells without IR treatment (Fig. 19). The results suggested that amino
acids mediated the mitotic entry possibly through the kinase activity of mTORC1.
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Figure 15 The mTOR activity is required for recovery from IR-induced G2 arrest
U2OS cells were incubated with DMSO, 20nM rapamycin or 1μM KU0063794 for 12
hours before exposed to IR (7Gy) and 2μM paclitaxel. We stained cells with PI and pH3 for mitotic entry analysis. The numbers indicated the percentages of positive p-H3
stained cells detected by flow cytometry. The ratio of mitotic cells in rapamycin or
KU0063794 groups was normalized to mitotic cells (%) in DMSO group at each time
point. Efficiency of mTOR inhibition by rapamycin or KU0063794 was detected by
western blot. ctrl: control; error bars represent mean ± SEM; n = 3 independent
experiments; * p<0.05
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Figure 16 The structure and the test of mTOR conditional knock-in cell line
The graphs illustrated genomic structures of mTOR conditional knock-in cell line
(D2338A-cKI) and primers (black arrows) identifying allele 1 and cre-excised allele 2.
We followed the manufacturer’s instruction to generate cells with mTOR kinase-dead
mutation (D2338A) using cre-lox recombination system. PCR products on the agarose
gel indicated efficiency of Cre recombinase.
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Figure 17 The mTOR kinase activity is required for the recovery from IR-induced
G2 arrest
mTOR kinase-dead conditional knock-in HCT116 cells (D2338A-cKI) were stabilized
after infected by Ad5-CMV-empty or Ad5-CMV-Cre virus particles (Vector Development
Laboratory). Stabilized cells were collected 3, 9 and 12 hours after IR (7Gy) and 2μM
paclitaxel treatment for mitotic entry analysis and western blot. The graph presented
the ratio of mitotic cells normalized to the parental cell line (wild-type HCT116) at
different time points. Error bars represent mean ± SD; n = 3 independent experiments;
* p<0.05
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Figure 18 The mTORC1 kinase activity is required for the recovery from IRinduced G2 arrest
U2OS cells with control, Raptor, Rictor, or mTOR siRNA (si-ctrl, si-Raptor, si-Rictor, or
si-mTOR) were exposed to IR (7Gy) plus 2μM paclitaxel for mitotic entry analysis and
western blot. The numbers shown in flow cytometry graphs were the percentages of pH3 (+) cells. The analysis is similar to previous description. Error bars represent mean
± SEM; n = 3 independent experiments; * p<0.05
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Figure 19 The amino acid withdrawal experiment confirmed that mTORC1 is
required for G2/M checkpoint recovery
U2OS cells were incubated with different low concentrations of amino acids (AA, the
regular medium contains 100%AA) for 28 hours, and these amino-acid-starved cells
were treated with IR (7Gy) and 2μM paclitaxel for mitotic entry analysis. The ratio of
mitotic cells in the bar graph was relative to the mitotic cell percentage of the 10% AA
medium group (set as 1). ctrl: control; error bars represent mean ± SD; n = 3 independent
experiments; * p<0.05
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3.4 mTORC1 functions as positive transcription regulator of CCNB1 and PLK1
To understand how mTORC1 controls expression of cell cycle regulators,
including Cyclin B1 and PLK1, we measured the mRNA levels of CCNB1 and PLK1
(encoding protein Cyclin B1 and PLK1) in U2OS cells. Both CCNB1 and PLK1 mRNA
levels decreased first and then increased after IR treatment. In mTOR-depleted cells,
the basal mRNA levels of CCNB1 and PLK1 were lower but the increase of mRNA
expression after IR was even less compared to control cells (Fig. 20). The change of
CCNB1 and PLK1 mRNA levels in Raptor-depleted cells was similar to the changes in
mTOR-depleted cells, but not in Rictor-depleted cells (Fig. 21). The results supported
that mTORC1 regulated CCNB1 and PLK1 expression at the transcription level.
We further performed the dual luciferase assay to validate the function of mTOR
in CCNB1 and PLK1 transcription regulation. The luciferase activities driven by CCNB1
and PLK1 promoters (CCNB1-luciferase, PLK1-luciferase) were lower in mTORdepleted cells (Fig. 22). On the other hand, PLK1-luciferase activities were higher in
cells overexpressing wild-type mTOR compared to cells overexpressing empty vector
or catalytic-dead mTOR (Fig. 23). The results indicated that the mTOR kinase activity
was involved in transcriptional regulation of cell cycle proteins.
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Figure 20 The mTOR expression level was associated with CCNB1 and PLK1
transcription
U2OS cells transfected with siRNAs were collected at different time points after IR
(7Gy) and 2μM paclitaxel treatment. CCNB1 and PLK1 mRNA levels were measured
by qPCR and normalized by actin. In the bar graphs, each normalized mRNA level of
CCNB1 or PLK1 was relative to the level in the si-ctrl group without treatment (ctrl in sctrl, set as 1). si-ctrl and si-mTOR: cells transfected with non-target control siRNA and
mTOR siRNA; ctrl: control; error bars represent mean ± SD; n = 3 independent
experiments; * p<0.05

58

Figure 21 The Raptor expression level was associated with CCNB1 and PLK1
transcription
The experiments were exactly the same with Figure 20, but U2OS cells were
transfected with different siRNAs. si-ctrl, si-Raptor, and si-Rictor: cells transfected with
non-target control siRNA, Raptor, and Rictor siRNA; ctrl: control; error bars represent
mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 22 The dual luciferase assay showed the requirement of mTOR in CCNB1
and PLK1 transcription regulation.
The dual-luciferase reporter assay was conducted in U2OS cells with control or mTOR
siRNA. The value of firefly-luciferase driven by the CCNB1 or PLK1 promoter was
normalized with the value of renilla-luciferase. In the bar graph, normalized values at
different time points were relative to the value in the si-ctrl group without IR treatment.
si-ctrl and si-mTOR: cells transfected with non-target control siRNA and mTOR siRNA;
ctrl: control; error bars represent mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 23 The dual luciferase assay confirmed the function of mTOR in CCNB1
and PLK1 transcription regulation through mTOR over-expression.
We also used dual-luciferase reporter assay in U2OS cells expressing control vector
(vector), wild-type mTOR (mTOR-WT) or kinase-dead mTOR (mTOR-KD) construct.
The normalized value in the vector group was set as 1. Error bars represent mean ±
SD; n = 3 independent experiments; * p<0.05
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3.5 mTOR controls transcription of CCNB1 and PLK1 through KDM4B
It is known that histone lysine demethylase 4B (KDM4B) activates transcription
of Myb-related protein B (B-myb)-regulated genes, such as CCNB1 and PLK1 (77). We
depleted either mTOR or KDM4B and treated U2OS cells with IR and paclitaxel. We
found that Cyclin B1 levels decreased during checkpoint recovery in KDM4B-depleted
cells and mTOR-depleted cells. KDM4B level decreased in mTOR-depleted cells but
mTOR level remained the same in KDM4B-depleted cells. The decrease of KDM4B in
mTOR-depleted cells was more dramatic during checkpoint recovery (Fig. 24). The
phenomenon was repeatable in HCT116 cells (Fig. 25). Cells treated with rapamycin
also decreased expression of KDM4B, but KDM4B level had no change when we
treated cells with AKT inhibitor, MK2206 (Fig. 26). It indicated that mTORC1 was the
major complex which controlled KDM4B expression. Next we depleted KDM4B and the
percentage of mitotic cells decreased after IR and paclitaxel treatment (Fig. 27). The
results suggested KDM4B could be a potential link between mTOR and transcriptional
control.
We then performed the ChIP-pPCR assay. The results showed that KDM4B was
associated with the 5’-untranslated region (5’-UTR) of CCNB1 close to the promoter
region, and the association was stronger 4 hours after IR treatment, which is earlier
than the increase of Cyclin B1 expression (Fig. 28). In the control group, the increased
association of KDM4B, the decreased association of H3K9me3, and the increased
association of B-myb with CCNB1 gene during G2/M checkpoint recovery suggested
that KDM4B epigenetically controlled expression of CCNB1. In the mTOR-depleted
group, the decrease of KDM4B, the increase of H3K9me3, and the decrease of B-myb
in downstream of CCNB1 promoter region suggested that decreased expression of
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KDM4B in mTOR-depleted cells affected the transcription of CCNB1 (Fig. 29). We then
treated cells with MG132, the proteasome inhibitor, and found that mTOR may regulate
KDM4B stability through proteasome (Fig. 30).
In mTOR-depleted cells, we did not observe the increase of IR-induced DNA
damage through comet assay (Fig. 31). The activations of ATM and ATR pathways
were also intact (Fig. 32). Protein expression of KDM4B, PLK1 and Cyclin B1 in ATMdepleted cells were relatively the same as expression in control cells (Fig. 33). The
results indicated that the function of mTOR in checkpoint recovery was independent to
DNA damage pathways which also controlled checkpoints.
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Figure 24 KDM4B linked mTOR to Cyclin B expression
U2OS cells transfected with siRNAs were collected at different time points after IR
(7Gy) and 2μM paclitaxel treatment for western blot. The bar graph showed the
normalized KDM4B protein expression level by Actin (the internal control) in each
group. si-ctrl, si-KDM4B and si-mTOR: cells transfected with non-target control siRNA,
KDM4B and mTOR siRNA; crtl: control; error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 25 Regulation of KDM4B expression by mTOR was not U2OS cell-specific
We depleted mTOR by an individual shRNA (sh-mTOR #193) or depleted KDM4B by
siRNA in HCT116 cells and treated cells with IR (7Gy) plus 2μM paclitaxel for western
blot.
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Figure 26 KDM4B expression was not affected by the AKT inhibitor
U2OS cells were pretreated with the AKT inhibitor MK2206 followed by IR (7Gy) and
2μM paclitaxel for immunoblot. ctrl: control
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Figure 27 KDM4B was required for mitotic entry after irradiation
U2OS cells with control or KDM4B siRNAs were exposed to IR (7Gy) and 2μM
paclitaxel for different periods of time. We stained cells with PI and p-H3 for mitotic
entry analysis. The numbers in flow cytometry representative graphs indicated the
percentages of positive p-H3 stained cells. In the bar graph, the percentages of mitotic
cells in the KDM4B-depletion group at each time point were normalized to the
percentages of mitotic cells in the control group. si-ctrl and si-KDM4B: cells transfected
with non-target control siRNA and KDM4B siRNA; crtl: control; error bars represent
mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 28 KDM4B was associated with CCNB1 gene
Quantitative ChIP in the 5’-untranslated region (5’-UTR) close to the CCNB1 promoter
region was performed at different time points after irradiation. R-IGG: rabbit
immunoglobulin G; ctrl: control; error bars represent mean ± SD; n = 3 independent
experiments
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Figure 29 KDM4B links mTORC1 to transcriptional control of CCNB1
U2OS cells treated with IR (7Gy) were collected for ChIP analysis using anti-KDM4B,
anti-H3K9me3 or anti-B-myb antibody. The immunoprecipitated DNA fragments were
amplified with the primer to CCNB1 gene (+86 to +187). The bar graphs represented
the amount of precipitated DNA normalized to total input chromatin. si-ctrl and simTOR: cells transfected with non-target control siRNA and mTOR siRNA; crtl: control;
error bars represent mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 30 Regulation of KDM4B expression by mTOR was probably through
proteasome degradation
U2OS cells were pretreated with the proteosome inhibitor MG132 followed by IR (7Gy)
and 2μM paclitaxel for immunoblot.
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Figure 31 mTOR depletion did not affect IR-induced DNA breaks and repairs
U2OS cells were transfected with control siRNA, mTOR siRNA, or without siRNA, and
were collected at different time points after IR (7Gy) for Comet assay. Representative
images showed the changes of comet tails after IR treatment. We counted 50 cells in
each group and statistical analysis was performed as the percentage of damaged cells
in each group. Mock: cells incubated with only the transfection reagent; si-ctrl and simTOR: cells transfected with non-target control siRNA and mTOR siRNA; ctrl: control;
error bars represent mean ± SD; n = 3 independent experiments
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Figure 32 mTOR depletion did not affect IR-induced DNA damage response
U2OS cells were transfected with control siRNA or mTOR siRNA. The immunoblot
showed the kinetics of the DNA damage response signaling after IR (7Gy). si-ctrl and
si-mTOR: cells transfected with non-target control siRNA or mTOR siRNA
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Figure 33 ATM depletion did not change expression of mitosis-related proteins
U2OS cells with control or ATM siRNAs were collected after IR (7Gy) and 2μM
paclitaxel treatment for western blot. Mock: cells incubated with only the transfection
reagent; si-ctrl and si-ATM: cells transfected with non-target control siRNA and ATM
siRNA
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3.6 The high mTOR kinase activity in TSC2-depleted cells promotes recovery
from irradiation-induced G2 arrest
TSC2

negatively

regulates

mTOR

signaling,

especially

the

mTORC1

complex(78). In order to test mitotic entry after irradiation in the condition of high mTOR
kinase activity, we treated TSC2-depleted (TSC2-/-) and TSC2-wild type (TSC2+/+) MEF
cells with IR and paclitaxel. The TSC2-/- group showed higher percentage of mitotic
cells after IR compared to the TSC2+/+ group and the difference were greater in the
longer period of time (Fig. 34). KDM4B, PLK1, and Cyclin B1 protein levels were higher
after IR treatment in TSC2-/- MEF cells (Fig. 35), and KDM4B was mostly located in the
nucleus (Fig. 36). The results were the same when we depleted TSC2 in U2OS cells
(Fig. 37). In conclusion, the balance of the mTOR kinase activity affects recovery from
IR-induced cell cycle arrest.
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Figure 34 TSC2 depletion facilitates G2/M checkpoint recovery-mitotic entry
analysis
Wild-type (TSC2 +/+) and Tsc2-/- (TSC2 -/-) MEFs were irradiated with 15Gy followed
by 2μM paclitaxel immediately at the time points indicated. Cells treated with paclitaxel
alone (“+taxol” group) were collected after 8-hour treatment. Cells entered the mitosis
phase were stained with p-H3 and detected by flow cytometer. The numbers in the
graphs indicated the percentages of p-H3 (+) cells. The ratio of mitotic cells at each
time point in the bar graph was normalized with the percentages of mitotic cells in wildtype MEFs (set as 1). ctrl: control; error bars represent mean ± SEM; n = 3
independent experiments; * p<0.05
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Figure 35 TSC2 depletion facilitates G2/M checkpoint recovery-western blot
Wild-type (TSC2 +/+) and Tsc2-/- (TSC2 -/-) MEFs were irradiated with 15Gy followed by 2μM
paclitaxel and collected at different time points for western blot. Actin and Tubulin were the
loading control. T: paclitaxel;
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Figure 36 The change of KDM4B expression was mainly in nuclei
Wild-type (TSC2 +/+) and Tsc2-/- (TSC2 -/-) MEFs treated with IR plus paclitaxel for two
hours were separated into nuclear and non-nuclear fractions by Dounce homogenizer.
GAPDH was used as the loading control in the non-nuclear fraction and H2AX was the
loading control of the nuclear fraction.
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Figure 37 TSC2 depletion promotes mitotic entry after IR-induced G2 arrest
We transfected either non-target control siRNA (si-ctrl) or TSC2 siRNA pool (si-TSC2)
oligos in U2OS cells and then treated cells with IR (7Gy) plus 2μM paclitaxel for a
period of time as the graphs indicated. Mitotic cells were defined as p-H3 (+) cells
which were detected by flow cytometer and the percentage in each sample was shown
in graphs. The ratio of mitotic cells in each group in the bar graph was normalized using
the same method as previous description. The level of p-H3 was also detected by
western blot. ctrl: control; error bars represent mean ± SEM; n = 3 independent
experiments; * p<0.05
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3.7 WEE1 inhibition is a therapeutic strategy for tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is a decease caused by inactivating
mutations in TSC2 which leads to constitutive mTORC1 activation (78). Given TSC2depleted cells with faster G2/M checkpoint recovery, we treated TSC2-/- and TSC2+/+
MEF cells [TSC2-knock out (TSC2-/-) vs. TSC2-wild type (TSC2+/+); TSC2-knock out
with the empty vector (TSC2 KO) vs. TSC2-knock out with reconstituted TSC2 (TSC2
KO+ rescue)] with the WEE1 inhibitor MK1775 to accelerate premature mitotic entry of
cells (79). Compared to TSC2+/+ MEF cells, TSC2-/- MEF cells were more sensitive to
MK1775 in MTT cell proliferation assay and the drug sensitivity was not due to WEE1
expression (Fig. 38). We also treated MEF cells with 0.2μM MK1775 after cells formed
3-dimentional structures in Matrigel and MK1775 caused stronger inhibition of cell
proliferation in TSC2-/- cells (Fig. 39). More rapid cell cycle progression (Fig. 40) with
persisted γ-H2AX (Fig. 41) in TSC2-/- MEF cells treated with 0.2μM MK1775 indicated
that cells bypassed the checkpoint with continuous activation of DNA damage signaling
pathways. In order to increase M1775 effects, we combined MK1775 with a PARP
inhibitor BMN 673, which caused DNA damage. TSC2-/- MEF cells were more sensitive
to the drug combination and the combination effect was better than any single drug (Fig.
42). More apoptotic cells were found in TSC2-/- MEF cells treated with two drugs by
Annexin V assay and Cytochrome c immunofluorescence staining (Fig. 43 and Fig. 44).
The result was similar when we combined MK1775 with another PARP inhibitor
olaparib (Fig. 45). Moreover, drug combination induced more multipolar mitosis and
multinucleated cells in TSC2-/- cells, which were the evidences of mitotic catastrophe
(Fig. 46). Due to all DNA damage-related dugs with carcinogenic effects, the treatment
with MK1775 plus BMN673 probably should be applied as the second line in TSC
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patients. We generated rapamycin-resistant line in rat ELT3 TSC2-/- cells (ELT3 V3
became ELT3 V3R, R as resistant) and treated cells with MK1775 or BMN 673. ELT3
V3R cells were still sensitive to the drug combination (Fig. 47). Those evidences
supported that WEE1 and PARP1 inhibition could be a potential treatment for TSC2
patients.
To further evaluate the drug effect in vivo, we inoculated either rat ELT3-V3
(TSC2 null) or ELT3-T3 (with re-constitutive TSC2) cells with luciferase in bilateral
posterior flanks of mice. Five weeks later we started treating mice until the average
tumor size of any group reached the maximum allowable size in the animal facility. The
body weight was monitored to evaluate the toxicity throughout the experiment.
Although the tumor weights in both ELT3-V3 and ELT3-T3 groups did not show any
significant changes after MK1775 treatment, tumor volumes and bioluminescence
levels were significantly decreased after MK1775 treatment in the ELT3-V3 group but
not in the ELT3-T3 group (Fig. 48). Therefore, WEE1 inhibition could be a potential
strategy for TSC treatment.
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Figure 38 TSC2-null cells were more sensitive to the WEE1 inhibitor-MTT assay
The basal levels of WEE1 in TSC2 wild-type and TSC2-null MEFs were relatively the
same. MEFs were treated with different concentrations of MK1775 in 96-well plates for
4 days and cell viability was measured by MTT assay. MK1775 sensitivity was
presented as the ratio to the untreated group in each cell line (set as 1). TSC2 +/+:
Tsc2+/+, Tsc2 wild-type; TSC2 -/- and TSC2 KO: Tsc2-/-, Tsc2 null; TSC2 KO + rescue:
Tsc2 null cells with re-constitutive Tsc2; error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 39 TSC2-null cells were more sensitive to the WEE1 inhibitor-3D culture
MEFs were embedded in Matrigel (Day 0) and started to treat with 0.2μM MK1775 from
Day 3. The medium with or without MK1775 was changed every three days. The
representative photos were taken on Day 10. The fluorescence value was measured by
adding 10μl of PrestoBlue in 96-well plates. The graph showed the ratio of treated to
untreated groups in each cell line. TSC2 +/+: Tsc2+/+, Tsc2 wild-type; TSC2 -/- and
TSC2 KO: Tsc2-/-, Tsc2 null; TSC2 KO + rescue: Tsc2 null cells with re-constitutive
Tsc2; error bars represent mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 40 TSC2-null cells with WEE1 inhibition showed faster cell cycle
progression into mitosis
MEFs treated with 0.2μM MK1775 were collected at different time points for cell cycle
analysis and mitotic entry analysis. Percentages of mitotic cells were shown in
representative graphs. TSC2 +/+: Tsc2+/+, Tsc2 wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null;
error bars represent mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 41 Prolonged WEE1 inhibition induced persistent DNA damage in TSC2null cells
MEFs treated with 0.2μM MK1775 were collected at different time points for western
blot. The graph indicated expression of γ-H2AX normalized by Actin in each group.
TSC2 +/+: Tsc2+/+, Tsc2 wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error bars represent
mean ± SD; n = 3 independent experiments
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Figure 42 TSC2-null cells were more sensitive to the WEE1 inhibitor combined
with the PARP inhibitor BMN 673-MTT assay
We treated MEFs with 50nM MK1775 and 50nM BMN 673 for 4 days for MTT assay.
Cell viability was defined as the ratio to the untreated group. TSC2 +/+: Tsc2+/+, Tsc2
wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 43 TSC2-null cells were more sensitive to the WEE1 inhibitor combined
with the PARP inhibitor BMN 673-apoptosis assay
MEFs were incubated with 50nM MK1775 or/and 50nM BMN 673 for 48 hours and
stained with annexin V and PI. Apoptotic cells were defined as annexin V positive cells.
TSC2 +/+: Tsc2+/+, Tsc2 wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error bars represent
mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 44 TSC2-null cells were more sensitive to the WEE1 inhibitor combined
with the PARP inhibitor BMN 673-Cytochrome c staining
MEFs were incubated with 50nM MK1775 or/and 50nM BMN 673 for 48 hours and
stained with Cytochrome c. The percentages of apoptotic cells were calculated based
on the positive staining of Cytochrome c and nucleus morphology. TSC2 +/+: Tsc2+/+,
Tsc2 wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 45 TSC2-null cells were more sensitive to the WEE1 inhibitor combined
with the PARP inhibitor olaparib-apoptosis assay
MEFs were incubated with 50nM MK1775 or/and 5μM olaparib for 48 hours for
apoptosis assay. TSC2 +/+: Tsc2+/+, Tsc2 wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error
bars represent mean ± SD; n = 3 independent experiments; * p<0.05
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Figure 46 The WEE1 inhibitor MK1775 combined with the PARP inhibitor BMN
673 induced stronger mitotic catastrophe in TSC2-null cells
MEFs were treated with 50nM MK1775 and 50nM BMN 673 for 48 hours and were
stained with α-Tubulin and DAPI. The numbers of centrosomes and nuclei in one cell
were calculated. The bar graphs showed the percentage of bipolar/multipolar cells and
the percentage of normal/multinucleated cells in each group. TSC2 +/+: Tsc2+/+, Tsc2
wild-type; TSC2 -/-: Tsc2-/-, Tsc2 null; error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 47 The combination effect was relatively similar in rapamycin-sensitive
and rapamycin-resistant TSC2-null cells
We treated rat ELT3 V3 (Tsc2 null, rapamycin sensitive), ELT3 T3 (re-expressing Tsc2),
and ELT3 V3R (Tsc2 null but rapamycin resistant) cells with 50nM MK1775 or 20nM
BMN673 for 4 days. Cell viability was measured by MTT assay and was defined as the
ratio to the untreated group in each cell line. Error bars represent mean ± SD; n = 3
independent experiments; * p<0.05
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Figure 48 TSC2-null tumors were more sensitive to the WEE1 inhibitor in vivo
ELT3-V3/T3-luciferase cells were injected into mice. Five weeks later, mice were
treated with the vehicle or 60mg/kg MK1775 once every two days for three weeks.
Body weights, tumor volumes using the formula (length x width2)/2, tumor weights, and
bioluminescence levels were monitored regularly. ELT3 V3: Tsc2 null; ELT3 T3: ELT3
V3 re-expressing Tsc2; error bars represent mean ± SD; n=6; * p<0.05
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CHAPTER 4
Discussion, Conclusions and Perspectives

We have utilized a multidisciplinary approach to identify potential molecules that
regulate checkpoint recovery from irradiation (Fig. 6). It includes a high-throughput
protein array, systemic protein network analysis and an appropriate mathematical
model. The reverse phase protein array (RPPA) provides a set of total protein and
posttranslationally modified protein expression data in a time series across different
types of cells (80). The problem is that existing RPPA data processing platforms
provide limited systematic tools to identify novel molecule pathways after quantification
and normalization. For example, MIRACLE is a biologist-friendly web interface but it
does not provide network analysis (81). RPPApipe, which is also a web-based pipeline,
only focuses on existing pathway analysis (82). In order to identify new upstream
targets which may not change their expression dramatically but control the dynamics of
the checkpoint recovery network in our RPPA data, we first screened possible
candidates through the linear regression model written in R (Fig. 8) and generated an
IPA causal network containing all of our candidates (Fig. 10). Although IPA also
provides algorithms to identify upstream regulatory molecules, the downstream
molecules are usually not specific (83). Here we try to identify important regulators
which specifically control cell-cycle related proteins, including Cyclin B1 and Cyclin D1.
The process is similar to the way we solve maximum flow problems in mathematics. It
involves finding a maximum flow (signaling cascade) through a flow network (signaling
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network) with a source (upstream molecule) and a sink (downstream molecule). The
method we chose is the Ford-Fulkerson algorithm, which repeatedly finds augmenting
paths in the network and improves the total amount of flow until the flow reaches the
maximum (Fig. 7-10. Detail explanations are in MATLAB files). The advantage of the
algorithm is that the sink (downstream molecule) can be either specific or non-specific.
Based on our needs, we applied the algorithm and identified that mTOR has the
maximum signaling cascade to both Cyclin B1 and Cyclin D1 (Fig. 10).
mTOR regulates cell growth and cell division in response to growth factors,
energy status, nutrients, and stress, and mTORC1 is the main complex that couples
the environment cues, especially the abundance of amino acids, to G1 cell cycle
progression (21, 31). The G2 phase is also a period related to cell growth and protein
synthesis. Usually it is relatively short compared to the G1 phase because cells in the
G2 phase only synthesize basic needs for mitosis and for cell survival after mitosis. In
fission yeast, it has been studied that the activities of Cell division cycle 25 (Cdc25) and
Wee1 are correlated with cell size and nutrition status in the control of the Cyclindependent kinase 1 (Cdk1)-cyclin B complex at G2/M transition (84-86). It is not
surprising that we have confirmed our RPPA data and showed that mTORC1, the
nutrient sensor, regulated G2/M checkpoint recovery through the control of Cyclin B1
and PLK1 expression (Fig. 11-19).
Activation of the CDK1-Cyclin B1 complex triggers mitosis and it is regulated by
the CDK1 activity and the Cyclin B1 level in the nucleus. CDK1 is activated through its
phosphorylation by CDC25 and is inhibited through its phosphorylation by WEE1/MYT1
(47). PLK1 controls both CDC25 and WEE1 and functions as a positive regulator of
CDK1. The level of Cyclin B1 is regulated by protein ubiquitination and the transcription
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activity. Cyclin B1 expression gradually reaches the peak when cells enter mitosis and
drops in the end of mitosis (87-88). In response to IR-induced DNA damage, ATM/ATR
signaling pathways inhibit CDK1 activity mainly through PLK1 gene transcription
repression and CDC25 degradation (44). DNA damage pathways also arrest cells in
the G2 phase through the decrease of CCNB1 (encoding Cyclin B1) mRNA level and
the decrease of nuclear Cyclin B1 (34). Once damage is repaired, cell cycle progresses
again. PLK1 and Cyclin B1 level should increase as well. In our studies, mTOR
depletion did not affect checkpoint activation, but checkpoint recovery. Recovery of
PLK1 and CCNB1 transcription through mTORC1 regulation was observed in mitotic
reentry after irradiation, and the dynamics matched the increase of mitotic populations
(Fig. 20-23).
mTOR also regulated expression of KDM4B, a histone demethylase selectively
demethylates H3K9me2/me3 to H3K9me1/me2 (Fig. 24-30). KDM4B (JMJD2B)
belongs to the Jumonji C domain (JMJD) family, which is comprised of at least thirty
members based on the presence of the JmjC (Jumonji C) domain and demethylates tri(me3), di- (me2) and mono- (me1) methylated histone H3 lysine 4 (H3K4), H3K9,
H3K27, H3K36 or H4K20 through a dioxygenase reaction mechanism requiring Fe2+,
O2 and 2-oxoglutarate (α-ketoglutarate, a Krebs’ cycle intermediate) (89). The location
of histone lysine methylation determines the binding specificity of JMJD demethylases.
Histone lysine methylation at different sites of the gene also affect gene transcription
activity (90). Thus, epigenetic control by histone lysine demethylase is a sophisticate
process and is usually cell type specific. KDM4B is only over-expressed in some types
of cancers, such as gastric, colorectal, lung, and bladder cancers, and the expression
level is correlated with the tumor size and the clinical stage. In gastric cancer, KDM4B
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depletion induces apoptosis with increased levels of p53 and p21. In colorectal cancer,
depletion of KDM4B causes DNA damage, cell cycle arrest and apoptosis. KDM4B also
promotes G1/S transition and cell growth in lung cancer (91). The increased level of
KDM4B in DNA damage contributes to radioresistance in certain types of cells, and the
involvement of KDM4B in DNA damage appears evolutionary conserved (92).
Therefore, KDM4B at least shows its importance in specific types of cancer and it is
related to DNA damage response. Previous studies have shown that the stability of
KDM4 family regulated by E3 ubiquitin ligases involves in key cellular process including
transcription, DNA damage response, and cell cycle progression (93-96). Here, mTOR
controlled transcription activities of CCNB1 and PLK1 during checkpoint recovery
through the increased association of KDM4B, decreased association of H3K9me3 and
increased association of the transcription factor B-myb with CCNB1 gene during
checkpoint recovery (Fig. 29). KDM4B expression regulated by mTOR was probably
through ubiquitin-dependent proteasomal degradation (Fig. 30) and more detail
mechanisms need to be done.
Another interesting point between KDM4B and mTOR is the energy status. The
function of the histone demethylase JMJD family, including KDM4B, requires 2oxoglutarate (α-ketoglutarate) (90). α-ketoglutarate is the intermediate in the Krebs
cycle, a series of oxidation-reduction reactions in mitochondria to eventually generate
ATP. The abundance of ATP controls mTORC1 activity and promote cell growth. That
is probably the reason that both KDM4B and mTOR are related to G1/S transition.
Since cells also synthesize proteins in the G2 phase, especially after DNA damage, the
energy status may affect G2/M checkpoint recovery through mTORC1 and KDM4B.
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In some of our results, mTOR seemed to control G2/M transition without any
stimulants but the effects were not as dramatic as effects when we treated cells with
irradiation. The limit is that we couldn’t exactly tell the phenomenon was due to late G1
cell cycle arrest in amino acids deprivation and mTORC1 inhibition (97), or it was due
to the function of mTOR directly in mitotic entry in physiological conditions. In cell cycle
analysis (data not shown), G1 arrest in mTOR-depleted cells was not as obvious as in
rapamycin-treated cells, but both conditions cause delayed mitotic entry during
recovery from irradiation and paclitaxel treatment. Cells treated with only paclitaxel had
relatively similar mitotic populations in control and mTOR-depleted cells, which
indicated that G1 arrest was not the main cause of delayed checkpoint recovery in
mTOR-depleted cells (Fig.11-14). KDM4B depletion itself did not cause the change of
basal cell cycle profile (data not shown), but affect mitotic entry after irradiation and
paclitaxel, which demonstrated the function of KDM4B in G2/M transition (Fig. 27).
These evidences strongly suggested that mTOR had its role at least in G2/M
checkpoint recovery after irradiation.
The severity of DNA damage and the activities of ATM/ATR signaling pathways
also control the G2/M checkpoint following irradiation (34, 98). Although it has been
known that mTOR inhibitors suppress homologous recombination (99), we did not
observe significant increase of DNA damage after IR in mTOR-depleted cells (Fig. 31).
It might be due to less sensitivity of comet assay, relatively low dosage of IR or the
existence of other repair mechanisms. Depletion of mTOR did not affect activation of
ATM/ATR pathways and the G2/M checkpoint, and depletion of ATM did not show the
changes of KDM4B, PLK1 and Cyclin B1. These evidences suggested that mTOR
depletion controlled checkpoint recovery instead of causing checkpoint adaptation, and
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also indicated that the function of mTOR in checkpoint recovery was ATM/ATR
independent (Fig. 32-33).
Tuberous sclerosis complex (TSC) is a rare genetic disease. Mutations in either
TSC1 or TSC2 are found in 85% of TSC patients, and the majority of patients have
TSC2 mutations (100). Patients with TSC usually have benign tumors during childhood
in many parts of bodies, including brain, kidney, and lung. More than 80% of TSC
patients have central nervous system complications, such as seizures, mental
retardation, and autism. Renal tumors cause the most lethal complications for TSC
patients. Around 80% of TSC patients develop bilateral renal angiomyolipoma,
hamartoma or cysts, leading to end-stage renal failure, massive bleeding or infection.
Few TSC2 patients, especially women, develop chronic obstructive pulmonary disease
due to pulmonary lymphangiomyomatosis (78). The treatment for TSC patients is either
surgery or symptomatic treatment. Inhibition of mTOR activity by rapalogs is one of few
strategies to control tumor growth in TSC patients. Everolimus has been approved by
FDA for only two indications. One indication is that adult TSC patients with renal
angiomyolipoma who are at risk of complications but do not require surgery. The other
indication is that any patients with subependymal giant cell astrocytomas who require
treatment but are unable to do surgery. However, rapalogs may cause severe adverse
reactions, such as the increased infection risk. It is a need to develop new treatment for
TSC patients (78, 100).
As previous description, WEE1 phosphorylates CDK1 and inhibits G2/M
transition. Inhibition of WEE1 by MK1775 (AZD1775) abrogates G2/M arrest resulting
in premature mitotic entry and mitotic catastrophe (55-56). Currently many studies
combine MK1775 with radiation therapy or different DNA damaging drugs, such as
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cisplatin and carboplatin, for cancer treatment. The effect is more pronounced in p53deficient cancers which have the G1 checkpoint defect and strongly depend on the G2
checkpoint to prevent cell cycle progression before damages are repaired (101-103). In
TSC2-depleted cells, the persistent high mTORC1 activity promotes G1/S transition
and may also facilitate G2/M checkpoint recovery after irradiation even under nutrient
and energy deprivation, the common condition in cancer (104). Thus, TSC2-depleted
tumors with faster G2/M checkpoint recovery are candidates for MK1775 treatment (Fig.
34-37). In our study, TSC2-depleted cells were more sensitive to MK1775 in vitro.
TSC2-depleted cells showed faster cell cycle progression and persistent DNA damage
after MK1775 treatment (Fig. 38-41). We combined MK1775 with the PARP inhibitor
(BMN673 or olaparib) which cause DNA damage, and the combination treatment
worked better compared to any single agent in TSC2-depleted cells. Although mitotic
catastrophe is the mechanism how cells maintain genome integrity, all DNA damage
and cell cycle-related reagents still have risks of developing cancer. We proposed that
MK1775 combined with PARP inhibitors were applied as the second-line treatment for
TSC patients, and so we generated rapamycin-resistant TSC2-depleted cells to test the
drug effects. In rapamycin-resistant TSC2-depleted cells, the sensitivity to combination
treatment was similar to parental TSC2-depleted cells, but the mechanisms could be
even more complicated (Fig. 42-47). We further tested drug combination in the mouse
model. Only MK1775 alone and BMN 673 alone (105) showed the therapeutic effect in
mice with TSC2-depleted tumors (Fig. 48, data only showed the MK1775 part). The
possible reason could be the way we combined these two drugs. We treated mice with
the PARP inhibitor and the WEE1 inhibitor simultaneously. Because TSC2-depleted
cells have relatively intact DNA repair machineries compared to other cancer cells, the
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way we apply drug combination probably should be the PARP inhibitor followed by the
WEE1 inhibitor. The PARP inhibitor is given first to accumulate sufficient DNA damage,
and then the WEE1 inhibitor releases the G2/M checkpoint to cause mitotic catastrophe.
Furthermore, the timing, the dosage, and the treatment course should also be tested,
since tuberous sclerosis complex forms benign tumors instead of cancers. Therefore,
more animal experiments may need to be done.
In conclusion, we have combined several disciplines to identify a novel
mechanism of mTOR signaling in regulating a transcriptional program required for
G2/M checkpoint recovery after DNA damage. It is one step forward to link
environmental cues outside the cell, signaling cascades in the cytoplasm, and genome
integrity in the nucleus together. This mechanism also provides a new therapeutic
approach for TSC patients using the WEE1 inhibitor, which has potential to be
translated into clinical trials (Fig. 49).
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Figure 49 The summary of the study
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